微侵袭性叶状癌的临床病理特征
Rachel Han1, Atif A Hashmi1, Hannah Y Wen1
1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Histopathology
|April 29, 2025
概括
微侵袭性叶状癌 (MILC) 是一种罕见的乳腺癌亚型. 这项研究发现,MILC是一种低转移风险的惰性瘤,通常是由于局部叶状癌引起的.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 放射学 放射学是一门学科.
背景情况:
- 微侵袭性叶状癌 (MILC) 是一种罕见的乳腺癌亚型.
- 它的病理和临床特征尚不清楚.
研究的目的:
- 确定MILC的临床和病理特征.
- 描述2009-2023年期间在一个机构诊断的MILC.
主要方法:
- 对30名被诊断患有MILC的女性患者进行了回顾性审查.
- 收集的数据包括人口统计,成像,病理学,生物标志物状态和随访.
- 排除患有先前或同步侵袭性癌症的患者.
主要成果:
- 平均年龄为53岁;微化是最常见的成像发现 (63%).
- 在10%的患者中,MILC是通过活检诊断出来的,而73%的患者是通过切除诊断出来的.
- 在90%的病例中与局部垂体癌 (LCIS) 相关;在21个哨戒淋巴结活检中没有淋巴结的参与.
- 大多数MILC都是ER+/PR+/HER2- (75%). 随访时间中位数为49个月;29/30名患者没有疾病迹象.
结论:
- 乳腺癌是一种相对惰的乳腺癌.
- 它源自经典和变体LCIS.
- 在MILC中,股或远程转移的风险较低.
相关概念视频
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...


